RxDoctor Payments DataLook up a doctor →

Tuba Esfandyari, MD

Gastroenterology · Kansas City, KSNPI 1740250778

Payments from drug & device makers

$1,039,060in general payments, 2019–2025

Across 289 payments — averaging $3595.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$233K
  • AbbVie$174K
  • Covidien LP$142K
  • Eli Lilly$137K
  • Amgen$125K
  • Takeda Pharmaceuticals U.S.A., Inc.$118K
  • plus $109K from 11 others
$12,995in research payments, 2019–2025

Across 1 payment — averaging $12,995 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Covidien LP$13K

What the payments were for

  • Travel & lodging$4,02989%
  • Food & beverage$3357%
  • Education$1523%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,039,060 in reported general payments places this provider in the 95th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$105,155
Medicare patients
483
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$321,336
CreonLipase/Protease/Amylase17$95,222
Humira(Cf) PenAdalimumab11$71,526
LinzessLinaclotide34$23,452
Famotidine72$4,754
Esomeprazole Magnesium54$3,703
Omeprazole200$3,558
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates46$3,151
Mesalamine15$2,883
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg126$2,707
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl93$1,398
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl52$948
Azathioprine19$831
Sucralfate28$803
Fluconazole17$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$199$321,33612 claims
AbbVieCreon, Linzess$174,296$118,67451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →